- Home
- HYPR vs QTTB Comparison
HYPR vs QTTB Comparison
Compare HYPR & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | QTTB |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 97.5M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HYPR | QTTB |
|---|---|---|
| Price | $1.60 | $11.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $1.59 | ★ $13.00 |
| AVG Volume (30 Days) | 482.3K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | $13,563,000.00 | ★ $53,737,000.00 |
| Revenue This Year | $50.75 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.68 | $1.40 |
| 52 Week High | $2.22 | $14.85 |
Technical Indicators
Market Signals| Indicator | HYPR | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 60.34 | 58.24 |
| Support Level | $1.39 | $2.93 |
| Resistance Level | $1.72 | $14.85 |
| Average True Range (ATR) | 0.09 | 1.55 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 94.77 | 29.40 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).